Stock Events

Stock Events

Mydecine Innovations Group 

€0.000000
50
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q2 2023
Next
-4.5
-4.16
-3.83
-3.5
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
1.81MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0NFA.MU. It's not an investment recommendation.
Vanguard S&P 500 Index
7
VFV.TO
Vanguard FTSE Canadian High Dividend Yield Index
7
VDY.TO
Microsoft
6
MSFT
NVIDIA
6
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.84B
Compass Pathways focuses on psilocybin therapy for mental health disorders, directly competing in the psychedelic medicine space with Mydecine Innovations.
AtaiBeckley
ATAI
Mkt Cap1.91B
ATAI Life Sciences is a biotech company working on mental health treatments using psychedelics, overlapping with Mydecine's focus areas.
GH Research
GHRS
Mkt Cap1.85B
GH Research focuses on developing 5-MeO-DMT therapies for depression, competing in the psychedelic treatment market.
Revive Therapeutics
RVVTF
Mkt Cap8.71M
Revive Therapeutics is exploring the use of psychedelics for medical treatments, including areas Mydecine Innovations is involved in.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is engaged in psychedelic production and therapy, directly competing with Mydecine's business model.
TripAdvisor
TRIP
Mkt Cap1.66B
Red Light Holland is involved in the production and sale of recreational truffles, indirectly competing by promoting psychedelic acceptance.

About

Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Show more...
CEO
ISIN
CA62849F1018

Listings

STU
DE
0NF1.STU
CN
CA
NVRS.CN
MU
DE
0NFA.MU
STU
DE
0NFA.STU

0 Comments

Share your thoughts

FAQ

What is Mydecine Innovations Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Mydecine Innovations Group stocks are traded under the ticker 0NFA.MU.
When is the next Mydecine Innovations Group earnings date?▼
Mydecine Innovations Group is going to release the next earnings report on August 17, 2026.
What were Mydecine Innovations Group earnings last quarter?▼
0NFA.MU earnings for the last quarter are -4.5 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Mydecine Innovations Group revenue for the last year?▼
Mydecine Innovations Group revenue for the last year amounts to 0 EUR.
What is Mydecine Innovations Group net income for the last year?▼
0NFA.MU net income for the last year is 1.81M EUR.
In which sector is Mydecine Innovations Group located?▼
Mydecine Innovations Group operates in the Other sector.
When did Mydecine Innovations Group complete a stock split?▼
Mydecine Innovations Group has not had any recent stock splits.